# Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder

> **NCT01382706** · PHASE2 · TERMINATED · sponsor: **University of Southern California** · enrollment: 15 (actual)

## Conditions studied

- Recurrent Bladder Cancer
- Stage III Bladder Cancer
- Stage IV Bladder Cancer
- Transitional Cell Carcinoma of the Bladder

## Interventions

- **DRUG:** docetaxel
- **DRUG:** lapatinib ditosylate
- **OTHER:** immunohistochemistry staining method
- **GENETIC:** fluorescence in situ hybridization
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01382706
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-06-13
- **Primary completion:** 2013-07-15
- **Final completion:** 2017-12-15
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Trial not progressing toward scientific goals
- **Last updated:** 2025-10-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01382706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01382706, "Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01382706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*